Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 6:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Tacrolimus and MMF Clear all
Recruiting Phase 2 Interventional

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

NCT07138898
View directory record Official record
Conditions
Rheumatic Disease
Interventions
Methotrexate, Sulfasalazine, Hydroxychloroquine, Leflunomide, Azathioprine, Mycophenolate, Cyclosporine, Tacrolimus, Etanercept, Adalimumab, Golimumab, Certolizumab, Infliximab, Rituximab, Belimumab, Tocilizumab, Anakinra, Canakinumab, Abatacept, Secukinumab, Ixekizumab, Bimekizumab, Ustekinumab, Guselkumab, Risankizumab, Tofacitinib, Upadacitinib
Drug · Biological
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 17, 2026, 6:33 AM EDT
Recruiting Phase 2 Interventional

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity

NCT04339777
View directory record Official record
Conditions
Lymphoproliferative Disorders, Autoimmune Lymphoproliferative, Immune System Diseases, Common Variable Immunodeficiency, Primary T-cell Immunodeficiency Disorders
Interventions
Busulfan test dose, Fludarabine, Busulfan, Alemtuzumab, Total body Irradiation, Allogeneic HSCT, Tacrolimus (Tacro), Mycophenolate mofetil (MMF), Cyclophosphamide (Cytoxan)
Drug · Radiation · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
4 Years to 69 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 17, 2026, 6:33 AM EDT
Completed Phase 2 Interventional Results available

Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies

NCT01341301
View directory record Official record
Conditions
Hematologic Malignancy
Interventions
Total Body Irradiation, Donor Lymphocyte Infusion (DLI), Cyclophosphamide, Tacrolimus, Mycophenolate mofetil, Allogeneic hematopoietic stem cell transplantation, Laboratory biomarker analysis
Radiation · Biological · Drug + 2 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Sep 17, 2026, 6:33 AM EDT
Recruiting Phase 2 Interventional

Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia

NCT06517641
View directory record Official record
Conditions
Severe Aplastic Anemia
Interventions
Haploidentical donor bone marrow transplant, Unrelated donor bone marrow transplant
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
3 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
25
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 17, 2026, 6:33 AM EDT
Completed Phase 4 Interventional Results available

Comparison of Tacrolimus Extended-Release (Envarsus XR) to Tacrolimus Immediate-Release in Human Leukocyte Antigen (HLA) Sensitized Kidney Transplant Recipients

NCT04225988
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
Extended-release tacrolimus, Immediate-release tacrolimus
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Sep 17, 2026, 6:33 AM EDT
Not listed Phase 1Phase 2 Interventional

Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation

NCT01983761
View directory record Official record
Conditions
Blood And Marrow Transplantation, Leukemia, Lymphoma, Transplantation Infection, Myelodysplastic Syndrome (MDS), Non-Hodgkin's Lymphoma (NHL), Hodgkin's Lymphoma
Interventions
Fludarabine, Clofarabine, Busulfan, ATG, TBI (Myeloablative), Fludarabine, Melphalan, ATG (Reduced Intensity)
Drug
Lead sponsor
Targazyme, Inc.
Industry
Eligibility
1 Year to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
4
States / cities
La Jolla, California • Cleveland, Ohio • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2013 · Synced Sep 17, 2026, 6:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

HLA-Identical Sibling Renal Transplant Tolerance

NCT00619528
View directory record Official record
Conditions
Immunosuppression, Kidney Transplantation, Graft Rejection
Interventions
Infusion of Donor Hematopoietic Stem Cells and Campath-1H
Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 17, 2026, 6:33 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Liver Transplantation With Tregs at UCSF

NCT03654040
View directory record Official record
Conditions
Liver Transplant
Interventions
arTreg, leukapheresis, cyclophosphamide, mesna, everolimus
Biological · Procedure · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Sep 17, 2026, 6:33 AM EDT
Completed Phase 4 Interventional

PK of MMF in Cadaveric vs Living Donor Liver Transplant Recipients

NCT00178425
View directory record Official record
Conditions
Transplantation, Liver
Interventions
Serial blood sampling as described in protocol, Estimation of Creatinine Clearance at regular intervals
Procedure
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 18, 2007 · Synced Sep 17, 2026, 6:33 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant

NCT03247088
View directory record Official record
Conditions
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Cyclophosphamide, Filgrastim, Fludarabine, Mycophenolate Mofetil, Sorafenib, Tacrolimus
Procedure · Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 17, 2026, 6:33 AM EDT
Completed Phase 4 Interventional Results available

Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients

NCT00866879
View directory record Official record
Conditions
Renal Transplant Rejection
Interventions
Sirolimus, Demographic Data, Medical History, and Donor Data, Blood Draws for Control Group, Blood Draws for Experimental Group, Donor Blood Draws, Donor Information, Kidney Biopsy
Drug · Other · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 70 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Sep 17, 2026, 6:33 AM EDT
No Longer Available No phase listed Expanded access

Immunosuppressive Medications for Participants in ITN005CT (NCT00014911)

NCT01309022
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Sirolimus, Tacrolimus, Mycophenolate mofetil, Mycophenolic acid
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
U.S. locations
3
States / cities
Miami, Florida • Boston, Massachusetts • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Sep 17, 2026, 6:33 AM EDT
Completed Not applicable Interventional Results available

Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor

NCT02880293
View directory record Official record
Conditions
Hematologic Malignancy
Interventions
melphalan, fludarabine, thiotepa, Cyclophosphamide, Mesna, Mycophenolate Mofetil, Filgrastim, Tacrolimus
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Sep 17, 2026, 6:33 AM EDT
Withdrawn Phase 2 Interventional

Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders

NCT05293509
View directory record Official record
Conditions
Stem Cell Transplantation
Interventions
Fludarabine, Dexamethasone, Cyclophosphamide, Bortezomib, Rituximab, Busulfan, Cyclophosphamide (Cy), Tacrolimus (or cyclosporine), Mycophenolate mofetil (MMF), Rabbit ATG
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 17, 2026, 6:33 AM EDT
Completed Phase 4 Interventional Results available

Trial to Evaluate Safety and Tolerability of Tacrolimus Extended-Release (Astagraf XL) in Human Leukocyte Antigen (HLA) Sensitized Kidney Transplant Recipients

NCT03194321
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Tacrolimus Extended-Release Oral Capsule
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Sep 17, 2026, 6:33 AM EDT
Completed No phase listed Observational

Myfortic, Prograf, and Corticosteroids in de Novo Liver Transplantation

NCT01467011
View directory record Official record
Conditions
End Stage Liver Disease
Interventions
Enteric-coated Mycophenolate Sodium
Drug
Lead sponsor
R. Mark Ghobrial, MD
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Sep 17, 2026, 6:33 AM EDT
Active, not recruiting Phase 1 Interventional

Immunological Tolerance in Patients With Mismatched Kidney Transplants

NCT05806749
View directory record Official record
Conditions
End Stage Kidney Disease, Immunological Tolerance, Kidney Transplant Failure and Rejection, Chronic Kidney Diseases
Interventions
Donor CD34+, CD3+. and belumosudil
Combination Product
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Sep 17, 2026, 6:33 AM EDT
Not listed Early Phase 1 Interventional

Vascularized Composite Allotransplantation for Treatment of Abdominal Wall Defects

NCT02416674
View directory record Official record
Conditions
Abdominal Wall Defect
Interventions
abdominal wall transplantation, Immunosuppressive Agents
Procedure · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 17, 2026, 6:33 AM EDT
Recruiting Phase 1Phase 2 Interventional

Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders

NCT03128996
View directory record Official record
Conditions
Severe Sickle Cell Disease, Bone Marrow Failure Syndromes, Metabolic Disorders, Immunologic Disorders, Hemoglobinopathies, Non-malignant Disorders
Interventions
RIC regimen, GVHD prophylaxis regimen
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
1 Day to 21 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2033
U.S. locations
4
States / cities
New Haven, Connecticut • Wilmington, Delaware • Grand Rapids, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 17, 2026, 6:33 AM EDT
Completed Phase 4 Interventional Results available

Multicenter Uveitis Steroid Treatment (MUST) Trial

NCT00132691
View directory record Official record
Conditions
Uveitis
Interventions
fluocinolone acetonide intraocular implant, oral corticosteroid with immunosuppressive agents as needed
Drug
Lead sponsor
JHSPH Center for Clinical Trials
Other
Eligibility
13 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
21
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2016 · Synced Sep 17, 2026, 6:33 AM EDT
Recruiting Phase 2 Interventional

Expanding Liver Transplant Immunosuppression Minimization Via Everolimus

NCT06280950
View directory record Official record
Conditions
Liver Transplant
Interventions
Everolimus, Tacrolimus (continued reduction), Tacrolimus (maintain 50% reduction)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
8
States / cities
Phoenix, Arizona • San Francisco, California • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 17, 2026, 6:33 AM EDT
Completed Not applicable Interventional Results available

Home-based Therapeutic Drug Monitoring in Kidney Transplantation

NCT05005221
View directory record Official record
Conditions
Kidney Transplant
Interventions
Automated text messages
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 99 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Sep 17, 2026, 6:33 AM EDT
Completed Phase 2 Interventional Results available

Belatacept Pilot Study in Lung Transplantation Immunosuppression in Lung Transplantation

NCT03388008
View directory record Official record
Conditions
Lung Transplant Rejection, Antibody-mediated Rejection
Interventions
Belatacept, Tacrolimus, ATG, Mycophenolate Mofetil, Methylprednisolone, Prednisone
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
St Louis, Missouri • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 24, 2022 · Synced Sep 17, 2026, 6:33 AM EDT
Active, not recruiting Phase 2 Interventional

Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita

NCT01659606
View directory record Official record
Conditions
Dyskeratosis Congenita, Hoyeraal Hreidarsson Syndrome, Revesz Syndrome, Aplastic Anemia
Interventions
alemtuzumab, Fludarabine, Cyclosporins, Mycophenolate mofetil, Tacrolimus
Biological · Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
30 Days to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2034
U.S. locations
11
States / cities
Chicago, Illinois • Boston, Massachusetts • Kansas City, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 17, 2026, 6:33 AM EDT